Home Data Calendar Blog

KNSA

Tables

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Earnings Per Share Basic -0.25 0.36 -0.20 0.21 -0.18 0.06 3.23 -0.29 -0.36 -0.52 -0.44 -0.61

Earnings Per Share Diluted -0.25 0.36 -0.20 0.21 -0.18 0.05 3.18 -0.29 -0.36 -0.52 -0.44 -0.61

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Revenue From Contract With Customer Excluding Assessed Tax 79.86 83.39 67.05 71.47 48.34 61.88 99.14 26.97 32.19 18.75 12.10 7.70

Revenues 79.86 83.39 67.05 71.47 48.34 61.88 99.14 26.97 32.19 18.75 12.10 7.70

Cost Of Goods And Services Sold 10.58 NA 9.09 7.70 7.04 NA 6.94 5.03 NA 3.87 2.77 2.47

Research And Development Expense 26.33 20.05 17.11 23.77 15.17 14.39 16.48 13.80 20.82 27.43 19.24 23.95

Selling General And Administrative Expense 38.68 36.74 34.47 29.18 29.05 27.21 24.68 23.84 22.22 22.74 20.76 21.85

Operating Income Loss -16.54 0.08 -10.93 -3.15 -11.20 6.05 46.41 -19.37 -23.32 -36.13 -30.67 -40.55

Allocated Share Based Compensation Expense 7.21 7.77 6.79 6.47 6.12 6.37 6.04 6.68 6.03 6.13 6.20 5.72

Income Tax Expense Benefit 3.43 -22.79 5.36 -16.21 2.91 2.38 -177.36 0.72 1.93 0.28 -0.12 1.01

Income Taxes Paid Net NA -1.31 0.20 3.52 3.20 6.08 1.31 NA NA 0.42 0.01 NA

Profit Loss -17.70 25.24 -13.86 14.97 -12.27 4.46 224.09 -19.98 -25.21 -36.33 -30.54 -41.56

Net Income Loss -17.70 25.24 -13.86 14.97 -12.27 4.46 224.09 -19.98 -25.21 -36.33 -30.54 -41.56

Comprehensive Income Net Of Tax -17.76 25.24 -13.87 14.93 -12.26 4.58 224.11 -19.97 -25.25 -36.35 -30.62 -41.52

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Assets 519.67 526.32 483.06 484.33 442.86 459.67 459.95 210.58 230.97 232.80 252.86 279.21

Liabilities 87.78 87.48 77.94 72.68 52.77 63.52 75.94 57.08 64.72 47.76 38.81 43.42

Liabilities And Stockholders Equity 519.67 526.32 483.06 484.33 442.86 459.67 459.95 210.58 230.97 232.80 252.86 279.21

Stockholders Equity 431.89 438.84 405.13 411.66 390.10 396.15 384.01 153.49 166.24 185.04 214.05 235.78

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Assets Current 270.59 276.30 256.11 246.04 231.50 243.06 241.81 179.94 198.76 196.45 217.51 244.81

Cash And Cash Equivalents At Carrying Value 141.08 107.95 117.83 112.57 80.62 122.72 175.76 94.31 63.32 122.47 190.18 167.95

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 141.08 107.95 117.83 112.57 80.62 122.72 175.76 94.31 63.32 122.47 190.18 168.16

Short Term Investments 72.47 98.42 83.26 72.42 106.88 67.89 24.96 43.90 82.25 59.73 10.00 57.91

Accounts Receivable Net Current 15.99 21.27 3.04 24.65 7.42 12.66 11.16 7.81 29.44 3.98 3.22 2.55

Inventory Net 27.28 31.12 25.58 23.96 23.43 21.60 14.62 19.92 13.22 3.67 5.61 6.38

Prepaid Expense And Other Assets Current 13.77 17.54 26.40 12.44 13.16 10.54 15.31 14.01 10.52 6.58 8.50 9.80

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Property Plant And Equipment Gross 8.65 8.52 8.65 8.58 8.54 8.52 8.60 8.58 8.75 8.75 8.98 8.88

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 7.94 7.79 7.73 7.44 7.15 6.86 6.61 6.43 6.27 5.92 5.81 5.44

Property Plant And Equipment Net 0.71 0.73 0.92 1.14 1.39 1.66 2.00 2.15 2.48 2.83 3.17 3.45

Finite Lived Intangible Assets Net 17.00 17.25 17.50 17.75 18.00 18.25 18.50 18.75 19.00 19.25 19.50 19.75

Other Assets Noncurrent 4.13 0.83 2.29 2.35 2.32 5.82 5.63 5.67 5.92 8.72 6.55 5.81

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Liabilities Current 64.21 63.67 53.47 47.47 36.59 47.07 56.49 43.54 50.35 44.82 34.43 38.78

Accounts Payable Current 5.63 8.25 1.01 0.65 1.39 7.90 1.47 2.52 3.38 1.87 1.65 4.16

Other Accrued Liabilities Current 0.41 0.33 0.28 0.25 0.07 0.13 0.58 0.37 0.33 0.37 0.32 0.36

Accrued Liabilities Current 44.72 44.67 41.15 35.32 20.89 30.11 30.87 34.50 38.89 38.03 28.53 31.06

Other Liabilities Current 11.43 8.19 6.43 4.60 4.33 5.75 8.79 3.19 4.77 1.54 1.00 0.93

Contract With Customer Liability Current 0.16 0.31 2.56 4.67 6.50 NA 12.09 NA NA NA NA NA

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Other Liabilities Noncurrent 1.89 1.86 1.95 1.92 1.88 1.84 1.82 0.26 0.27 0.27 0.89 1.14

Operating Lease Liability Noncurrent 9.86 10.01 10.65 11.28 2.13 2.62 3.44 1.28 2.10 2.67 3.50 3.50

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Stockholders Equity 431.89 438.84 405.13 411.66 390.10 396.15 384.01 153.49 166.24 185.04 214.05 235.78

Additional Paid In Capital 927.58 916.76 908.29 900.96 894.33 888.12 880.55 874.15 866.93 860.48 853.14 844.26

Retained Earnings Accumulated Deficit -495.65 -477.95 -503.19 -489.33 -504.30 -492.03 -496.50 -720.59 -700.61 -675.40 -639.06 -608.52

Accumulated Other Comprehensive Income Loss Net Of Tax -0.05 0.01 -0.00 0.01 0.06 0.04 -0.07 -0.09 -0.10 -0.07 -0.04 0.03

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 7.21 NA 6.79 6.47 6.12 NA 6.04 6.68 6.03 NA 6.20 5.72

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Net Cash Provided By Used In Operating Activities 3.99 4.33 16.99 -3.74 -4.27 -11.58 62.05 -7.82 -36.85 -18.88 -28.51 -38.78

Net Cash Provided By Used In Investing Activities 25.52 -14.89 -12.28 35.53 -37.92 -42.66 19.04 38.27 -22.72 -50.04 47.85 85.99

Net Cash Provided By Used In Financing Activities 3.61 0.69 0.55 0.16 0.09 1.19 0.36 0.54 0.42 1.21 2.68 0.89

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Net Cash Provided By Used In Operating Activities 3.99 4.33 16.99 -3.74 -4.27 -11.58 62.05 -7.82 -36.85 -18.88 -28.51 -38.78

Net Income Loss -17.70 25.24 -13.86 14.97 -12.27 4.46 224.09 -19.98 -25.21 -36.33 -30.54 -41.56

Profit Loss -17.70 25.24 -13.86 14.97 -12.27 4.46 224.09 -19.98 -25.21 -36.33 -30.54 -41.56

Increase Decrease In Accounts Receivable -5.27 18.23 -21.61 17.23 -5.24 1.50 3.35 -21.63 25.45 0.69 0.67 NA

Increase Decrease In Inventories -3.84 5.54 1.62 0.53 1.83 6.98 -5.29 6.69 9.55 -1.93 -0.78 NA

Increase Decrease In Accounts Payable -2.66 7.23 0.36 -0.74 -6.51 6.43 -1.05 -0.86 1.51 0.25 -2.54 3.58

Deferred Income Tax Expense Benefit 4.37 -25.71 10.29 -19.44 1.08 0.35 NA NA NA NA NA NA

Share Based Compensation 7.21 7.77 6.79 6.47 6.12 6.37 6.04 6.68 6.03 6.13 6.20 5.72

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Net Cash Provided By Used In Investing Activities 25.52 -14.89 -12.28 35.53 -37.92 -42.66 19.04 38.27 -22.72 -50.04 47.85 85.99

Payments To Acquire Property Plant And Equipment 0.08 0.06 0.02 0.03 0.02 -0.03 0.02 NA NA 0.25 0.05 0.06

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Net Cash Provided By Used In Financing Activities 3.61 0.69 0.55 0.16 0.09 1.19 0.36 0.54 0.42 1.21 2.68 0.89

2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30

Revenues 79.86 83.39 67.05 71.47 48.34 61.88 99.14 26.97 32.19 18.75 12.10 7.70

Collaboration 0.97 12.18 2.24 16.98 5.69 21.95 65.71 0.00 10.00 NA NA NA

Product 78.89 71.22 64.80 54.49 42.66 39.94 33.42 26.97 22.19 18.75 12.10 7.70

Collaboration, Territory License Rilonacept 0.19 NA NA NA NA NA NA NA NA NA NA NA

Collaboration, Worldwide License Vixarelimab 0.10 NA NA NA 5.69 NA NA NA NA NA NA NA

Revenue From Contract With Customer Excluding Assessed Tax 79.86 83.39 67.05 71.47 48.34 61.88 99.14 26.97 32.19 18.75 12.10 7.70

Collaboration 0.97 12.18 2.24 16.98 5.69 21.95 65.71 0.00 10.00 NA NA NA

Product 78.89 71.22 64.80 54.49 42.66 39.94 33.42 26.97 22.19 18.75 12.10 7.70

Collaboration, Territory License Rilonacept 0.19 NA NA NA NA NA NA NA NA NA NA NA

Collaboration, Worldwide License Vixarelimab 0.10 NA NA NA 5.69 NA NA NA NA NA NA NA

Plots across concepts

IncomeStatement

Comprehensive Income Net Of Tax

Expenses

Income Tax Expense Benefit

Balance Sheet

Operating Lease Right Of Use Asset

Assets

Property Plant And Equipment Net

Current Assets

Prepaid Expense And Other Assets Current

NonCurrent Assets

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

Property Plant And Equipment Net

Liabilities

Liabilities Current

Current Liabilities

Contract With Customer Liability Current

Stockholders Equity

Retained Earnings Accumulated Deficit

CashFlow

Net Income Loss

NetCashProvidedByUsedInOperatingActivities

Net Income Loss

NetCashProvidedByUsedInInvestingActivities

Payments To Acquire Property Plant And Equipment

OperatingLeaseLiability

Operating Lease Liability Current

FiniteLivedIntangibleAssets

Finite Lived Intangible Assets Accumulated Amortization

InventoryNet

Inventory Raw Materials Net Of Reserves

Line plots across dimensions of each concept